Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
03/2005
03/31/2005US20050069943 101 human secreted proteins
03/31/2005US20050069942 Vaccine vector comprising isolated nucleic acid molecule which encodes sequence 2 linked to promoter
03/31/2005US20050069929 Methods and compositions for seamless cloning of nucleic acid molecules
03/31/2005US20050069928 Methods for synthesis of defined polynucleotides
03/31/2005US20050069919 Novel human secreted proteins and polynucleotides encoding the same
03/31/2005US20050069893 Diagnostic method for glaucoma
03/31/2005US20050069878 Proteins associated with cell growth, differentiation, and death
03/31/2005US20050069866 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
03/31/2005US20050069865 Synthetic hcv envelope proteins and their use for vaccination
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069569 Osteocalcin; enzyme inhibitors; promote bone, teeth growth; administering Dna gene
03/31/2005US20050069559 Lawsonia intracellularis vaccine
03/31/2005US20050069557 A protein neuroglobin derived from neuronal tissue; binging, storage oxygen; therapy for central nervous system disorders
03/31/2005US20050069527 Cell-based therapies for ischemia
03/31/2005US20050069526 Promoting Recovery from Damage to the Central Nervous System
03/31/2005US20050069523 Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)
03/31/2005CA2579638A1 Rna interference targeting non-disease causing single nucleotide polymorphisms within a gene encoding a gain-of-function mutant huntingtin protein
03/31/2005CA2540129A1 Pharmaceutical delivery system
03/31/2005CA2539127A1 Receptor
03/31/2005CA2539066A1 Delivering genetic material to a stimulation site
03/31/2005CA2538840A1 Dna vaccine compositions and methods of use
03/31/2005CA2538729A1 Compound and method for treating androgen-independent prostate cancer
03/31/2005CA2538252A1 4'-thionucleosides and oligomeric compounds
03/31/2005CA2537085A1 Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina)
03/31/2005CA2526862A1 Methods of diagnosing, prognosing and treating breast cancer
03/31/2005CA2526834A1 Recombinant influenza vectors with a polii promoter and ribozymes
03/30/2005EP1518937A1 Increasing the concentration of a nucleic acid molecule
03/30/2005EP1518933A1 Vectors and methods for gene transfer to cells
03/30/2005EP1517992A2 Retrons for gene targeting
03/30/2005EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
03/30/2005EP1517912A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
03/30/2005EP1517606A2 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
03/30/2005EP1487976A4 Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides
03/30/2005EP1392341B1 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof
03/30/2005EP1389909A4 Antimicrobial compounds and methods for their use
03/30/2005EP1216299B1 Gene transfer in human lymphocytes using retroviral scfv cell targeting vectors
03/30/2005EP1203088B1 Conditionally controlled, attenuated hiv vaccine
03/30/2005EP1200105B1 Modified factor viii
03/30/2005EP1183361B1 Gene therapy of pulmonary disease
03/30/2005EP1001978B1 Angiotensin derivatives
03/30/2005EP0928290B1 Oligoribonucleotides and ribonucleases for cleaving rna
03/30/2005EP0585415B1 Dna encoding a human 5-ht 1e receptor and uses thereof
03/30/2005CN1602427A Inhibition of tristetraproline for protection of the heart from cardiac injuries
03/30/2005CN1602351A Islet cells from human embryonic stem cells
03/30/2005CN1602315A Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
03/30/2005CN1602207A Methods for inhibiting ocular processes
03/30/2005CN1602203A Use of gp130 activators in diabetic neuropathy
03/30/2005CN1600857A RIP5 gene and usage
03/30/2005CN1600789A Promotive factor for activating NF-kappa B and usage
03/30/2005CN1600788A Distinguishing gene for adjusting and controlling anti-oncogene p53 and usage
03/30/2005CN1195056C Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method
03/30/2005CN1194762C Gene therapy for cerebrovasclar disorders
03/29/2005US6872814 Chlamydia antigens and corresponding DNA fragments and uses thereof
03/29/2005US6872558 Heparanase-2 a member of the heparanase protein family
03/29/2005US6872547 Functional balanced-lethal host-vector systems
03/29/2005US6872528 Cell culture; for use as tool in gene therapy and cel packaging
03/29/2005US6872395 Viruses comprising mutant ion channel protein
03/29/2005US6872391 Nucleotide sequences coding polypeptide for use in the treatment of eating disorders
03/29/2005CA2425745C Expression of exogenous polynucleotide sequences in a vertebrate
03/29/2005CA2372409C Delivery of macromolecules into cells
03/29/2005CA2049287C Expression of exogenous polynucleotide sequences in a vertebrate
03/26/2005CA2441695A1 Regulation of matrix metalloproteinases by psp94 family members
03/24/2005WO2005026388A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases
03/24/2005WO2005026371A1 Method of transferring biological substance and transformation method using the method of transferring biological substance
03/24/2005WO2005026362A2 Lymphatic and blood endothelial cell genes
03/24/2005WO2005026355A1 Method of evaluating cancerization degree
03/24/2005WO2005026354A1 Method of evaluating cancerization degree
03/24/2005WO2005026350A1 Method of evaluating cancerization degree
03/24/2005WO2005026337A2 Adenoviral vector for infecting cells deficient in a car receptor
03/24/2005WO2005026331A2 Method of preparation of pharmaceutically grade plasmid dna
03/24/2005WO2005026320A2 Entrapped stem cells and uses thereof
03/24/2005WO2005026253A2 Labile linkage for compound delivery to a cell
03/24/2005WO2005026202A1 Compositions comprising a fragment of the herpesviral protein vp22 for delivery of substances to cells
03/24/2005WO2005025624A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
03/24/2005WO2005025611A1 Inhibitors of pace4 for the treatment of arthritis
03/24/2005WO2005025610A1 Use of markk or markk antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of mark or tau protein
03/24/2005WO2005025602A1 METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH
03/24/2005WO2005025495A2 Methods and compositions for blocking progression of a disease state
03/24/2005WO2005007824A3 Mutants of vaccinia virus as oncolytic agents
03/24/2005WO2005000336A3 The use of caldag-gefi inhibitors as antithrombotic agents
03/24/2005WO2005000215A3 Methods for treating pain
03/24/2005WO2004111270A3 Differential gene expression in schizophrenia
03/24/2005WO2004111074A9 In vivo production of a clostridial neurotoxin light chain peptide
03/24/2005WO2004108893A3 Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
03/24/2005WO2004101766A3 Grp94-based compositions and methods of use thereof
03/24/2005WO2004098509A3 Compositions for inducing immune responses
03/24/2005WO2004083240A3 Regulation of gene expression
03/24/2005WO2004076644A3 A composition for delivering an agent to a target cell and uses thereof
03/24/2005WO2004073641A3 Induced activation in dendritic cells
03/24/2005WO2004072248A3 A process for delivering sirna to cardiac muscle tissue
03/24/2005WO2004065549A3 Small interference rna gene therapy
03/24/2005WO2004062474A3 Smooth muscle cell differentiation with crp, srf and gata factors
03/24/2005WO2004044134A3 Phosphorous-linked oligomeric compounds and their use in gene modulation
03/24/2005WO2004041065A3 METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
03/24/2005WO2004020591A3 Methods of use for novel human polypeptides encoded by polynucleotides
03/24/2005WO2003045973A8 Peptides with growth inhibitory action
03/24/2005WO2002058450A3 Regulation of cell growth by muc1
03/24/2005US20050066375 Genetic engineered rodent comprising gene sequences coding antigenic recognition and/or cell activation of T cell polypeptide for use in treatment and prevention of infection, viral, nervous system and inflammatory diseases
03/24/2005US20050065107 Plasmids suitable for IL-2 expression
03/24/2005US20050065102 Medicinal compositions
1 ... 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 ... 870